In a recent phase I trial, Perez et al. demonstrated that the AE37 vaccine is safe and induces HER-2/neu-specific immunity in a heterogeneous population of HER-2/neu+ prostate cancer patients [125]. Here, ERBB2 is linked to prostate carcinoma.